All In Biotech

NDA 218614 · Ionis Pharms INC

Tryngolza (Autoinjector)

Olezarsen Sodium · Subcutaneous

NovelBreakthrough therapyPriority reviewOrphan

CDER novel approval, Dec 19, 2024: To treat familial chylomicronemia syndrome

Last checked: Nov 20, 2026Latest source record: Jun 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Dec 19, 2024

Approved uses

2

Original approval plus efficacy supplements

Registered trials

10

8 Phase 3, 1 recruiting

FAERS reports

947

201 serious, 4 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 3, 2026.

TRYNGOLZA ® is indicated as an adjunct to diet: To reduce triglycerides (TG) in adults with familial chylomicronemia syndrome (FCS). To reduce TG and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG: TG greater than or equal to 500 mg/dL). TRYNGOLZA is an apolipoprotein C-III (apoC-III)-directed antisense oligonucleotide (ASO) indicated as an adjunct to diet: To reduce triglycerides (TG) in adults with familial chylomicronemia syndrome (FCS). ( 1 ) To reduce TG and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG: TG greater than or equal to 500 mg/dL). ( 1 )

Mechanism: Olezarsen is an ASO-GalNAc 3 conjugate that binds to apoC-III mRNA leading to mRNA degradation and resulting in a reduction of serum apoC-III protein. Reduction of apoC-III protein leads to increased clearance of plasma TG and very low-density lipoprotein (VLDL).

Therapeutic areas: Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 24, 2026 Supplement 4 · Efficacy · priority review Breakthrough therapyOrphanLetterLabel
  • Dec 19, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
2 products under this application
  • TRYNGOLZA (AUTOINJECTOR) · OLEZARSEN SODIUM EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • TRYNGOLZA (AUTOINJECTOR) · OLEZARSEN SODIUM EQ 50MG BASE/0.8ML (EQ 50MG BASE/0.8ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Olezarsen" as an intervention, any sponsor and status, largest first.

All 10 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • injection site pain84
  • blood triglycerides increased82
  • injection site erythema77
  • product dose omission issue63
  • off label use57
  • arthralgia40
  • nausea36
  • pancreatitis35
  • pancreatitis acute34
  • injection site swelling33
  • fatigue30
  • injection site rash30

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2025152
2026795

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 26 on PubMed

Sponsor: Ionis Pharmaceuticals

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.